iver injury in mild COVID-19 with various COVID pandemic phases, a real-world study.
- Conditions
- To evaluate in the proportion of patients with COVID-19 infection and hospitalized in the hospital, hospital field, and cohort ward with liver injury due to a variety of real-world anti-COVID-19 medications and other consequences of COVID-19 infection.COVID-19, liver injury, Andrographis paniculata, Favipiravir, Ivermectin, Remdesivir, and Monulpiravir.
- Registration Number
- TCTR20230320008
- Lead Sponsor
- avamindradhiraj University Research Fund
- Brief Summary
We report more than a third of the cases are associated with mild liver injuries. Even liver-specific of ALT, our report a greater AST than ALT.Several patients with liver damage had modest baseline transaminitis; nevertheless, this was not a barrier to initiating medication.Only four (14.8%) of the previous liver disease had baseline compensated cirrhosis, and none had significant transaminitis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 300
Eligible individuals were inpatients age >18 years, who were admitted to the hospitel, hospital field, and cohort ward after RT-PCR testing confirmed the diagnosis of COVID-19 infection. For hospitel and hospital fields, symptomatic COVID-19 without pneumonia, and absence of risk factors for severe disease are inclusion criteria. Any of the following cohort wards qualify for symptomatic COVID-19 treatment: having severe illness risk factors or with mild pneumonia.
1.Patients with pneumonia and hypoxia will require an oxygen supplement
2.Patients with moderate to severe pneumonia (infiltration > 20% of total lung)
3.Pregnant or breast- feeding women.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method